NewsRelease
NatureArticle Cites Cleanascite™ to Investigate Serum Lipid FactorsLinking Ageing and Cancer Progression
MONMOUTHJUNCTION, NJ, August27, 2020 -- Biotech Support Group reports on an article published inNature, describing the simplicity and efficiency of their lipidclearance sample preparation technology for studying aggressivefactors associated with serum and ageing. The citation is:
Gomes,Ana P., et al. "Age-induced accumulation of methylmalonic acidpromotes tumour progression." Nature (2020): 1-5.https://doi.org/10.1038/s41586-020-2630-0
Therisk of cancer and associated mortality increases substantially inhumans from the age of 65 years onwards. The authors describehow metabolic alterations that occur with age can produce a systemicenvironment that favors the progression of tumors. Specifically, thatmethylmalonic acid (MMA), a by-product of propionate metabolism, isupregulated in the serum of older people and functions as a mediatorof tumor progression. To support this analysis, the authors state “HS(human serum) samples were manipulated to assess the components …that might facilitate entrance of MMA into cells. To delipidate theHS, Cleanascite Lipid Removal Reagent (Biotech Support Group) wasused according to the manufacturer’s protocol …, using a 1:4volume ratio of Cleanascite reagent to sample”. 
The authorsconclude that depletion of lipidic structures from serum taken froman older population, resulted in a reduction in total serum MMAlevels and was sufficient to abrogate the pro-aggressive phenotype.The data show that MMA, complexed with lipidic structures, is acirculatory factor that contributes to the pro-aggressive effects ofageing in cancer cells and is sufficient to drive tumor progressionand aggressiveness. Thus, MMA is a promising therapeutic target foradvanced carcinomas.
“Itsrewarding to see another reference whereby Cleanascite™ helped toidentify a characteristic feature of tumor aggressiveness. AsCleanascite™ is an aqueous suspension product without harmfulsolvents, one can use it to challenge cells for responsiveness. Thisultimately helps researchers decide whether or not lipids, or factorsinteracting with lipids, impart characteristic changes in cancercells. This information will hopefully help our understanding of howto reprogram the tumor microenvironment for therapeutic benefit.”states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.
Todownload whitepaper entitled “Cleanascite™- Lipid Removal and Cell Response Applications”,visit:
http://www.biotechsupportgroup.com/v/vspfiles/temp...
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lip...
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com.
ForBusiness Development,contact:
MatthewKuruc 732-274-2866, [email protected]